Market Overview:
The global pulmonary arterial hypertension (PAH) treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of PAH, rising awareness about PAH, and technological advancements in the field of PAH treatment. The global pulmonary arterial hypertension (PAH) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into vasodilators, phosphodiesterase 5 inhibitors (PDE 5 inhibitors), endothelin receptor antagonists (ERA), and soluble guanylate cyclase stimulator (SGC stimulator). The vasodilators segment dominates the global pulmonary arterial hypertension treatment market owing to their high usage rates for treating PAH symptoms. On the basis of application, hospital pharmacies accounted for majority share in 2017 owing to increased use of drugs for treating critical patients in hospitals.
Product Definition:
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the lungs. It is a rare condition that affects about 1 in 2,000 people. PAH can cause shortness of breath, chest pain, and fatigue. Treatment for pulmonary arterial hypertension includes medications and sometimes surgery.
Vasodilators:
Vasodilators are the drugs that widen the blood vessels and increase the flow of blood in them. The most commonly used vasodilators are nitroglycerin, isosorbide dinitrate, and avapritinib. Avapritinib (Iscenso) has been approved by FDA for treatment-resistant hypertension; however, there is a risk of heart attack or stroke with its use.
Phosphodiesterase 5 (PDE 5) Inhibitors:
Phosphodiesterase 5 (PDE5) inhibitors are the drugs that act by limiting the breakdown of cyclic adenosine monophosphate (cAMP). By inhibiting PDE5, these drugs enhance cAMP levels, which results in increased pulmonary arterial hypertension (PAH) response.
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacy segment is expected to witness the highest growth over the forecast period owing to various benefits offered such as convenience and flexibility. However, treatment in a hospital setting with conventional medications is preferred over an outpatient setting due to higher expertise and monitoring required for pulmonary hypertension patients.
The hospital pharmacy was estimated as the largest segment in 2017 owing to factors such as availability of advanced healthcare facilities along with highly skilled personnel at relatively low costs which enables better management of PHT cases compared to other settings. Furthermore, increasing prevalence of chronic diseases along with rising geriatric population groups are anticipated to drive demand from this sector over the forecast period thereby contributing towards revenue generation for this market.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large patient pool, high awareness levels coupled with easy access to quality treatment. Moreover, favorable reimbursement policies for PHA drugs and devices are also expected to fuel growth during the forecast period. Europe is estimated to be the fastest-growing region during the forecast period due to rising geriatric population base and increasing prevalence of pulmonary hypertension in this region as compared to other regions.
Major key players operating across this industry include Pfizer Inc.
Growth Factors:
- Increasing prevalence of pulmonary arterial hypertension (PAH) due to changing lifestyle and increasing awareness about the disease.
- Growing demand for PAH drugs owing to their better efficacy and safety profile as compared to the older generation drugs.
- Technological advancements in PAH treatment such as introduction of novel therapies and devices that are helping in improving the outcomes for patients with PAH.
- Rising number of clinical studies being conducted on new drug molecules for the treatment of PAH, which is resulting in increased adoption of these drugs by physicians worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Arterial Hypertension Treatment Market Research Report
By Type
Vasodilators, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), Soluble Guanylate Cyclase (SGC) Stimulator
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
GlaxoSmithKline plc, Eli Lilly and Company, Pfizer Inc.Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc, Bayer AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Pulmonary Arterial Hypertension Treatment Market Report Segments:
The global Pulmonary Arterial Hypertension Treatment market is segmented on the basis of:
Types
Vasodilators, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), Soluble Guanylate Cyclase (SGC) Stimulator
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline plc
- Eli Lilly and Company
- Pfizer Inc.Actelion Inc
- United Therapeutic Corporation
- SteadyMed Ltd
- Gilead Sciences, Inc
- Teva Pharmaceuticals Inc
- Bayer AG
Highlights of The Pulmonary Arterial Hypertension Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vasodilators
- Phosphodiesterase 5 (PDE 5) Inhibitors
- Endothelin Receptor Antagonists (ERA)
- Soluble Guanylate Cyclase (SGC) Stimulator
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Arterial Hypertension Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pulmonary arterial hypertension (PAH) is a condition in which the pressure inside the arteries of the lungs increases to a level that can damage them. Treatment for PAH typically includes medications and, in some cases, surgery.
Some of the major players in the pulmonary arterial hypertension treatment market are GlaxoSmithKline plc, Eli Lilly and Company, Pfizer Inc.Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc, Bayer AG.
The pulmonary arterial hypertension treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Arterial Hypertension Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pulmonary Arterial Hypertension Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pulmonary Arterial Hypertension Treatment Market - Supply Chain
4.5. Global Pulmonary Arterial Hypertension Treatment Market Forecast
4.5.1. Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pulmonary Arterial Hypertension Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pulmonary Arterial Hypertension Treatment Market Absolute $ Opportunity
5. Global Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
5.3.1. Vasodilators
5.3.2. Phosphodiesterase 5 (PDE 5) Inhibitors
5.3.3. Endothelin Receptor Antagonists (ERA)
5.3.4. Soluble Guanylate Cyclase (SGC) Stimulator
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pulmonary Arterial Hypertension Treatment Demand Share Forecast, 2019-2026
9. North America Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
9.7.1. Vasodilators
9.7.2. Phosphodiesterase 5 (PDE 5) Inhibitors
9.7.3. Endothelin Receptor Antagonists (ERA)
9.7.4. Soluble Guanylate Cyclase (SGC) Stimulator
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pulmonary Arterial Hypertension Treatment Demand Share Forecast, 2019-2026
10. Latin America Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
10.7.1. Vasodilators
10.7.2. Phosphodiesterase 5 (PDE 5) Inhibitors
10.7.3. Endothelin Receptor Antagonists (ERA)
10.7.4. Soluble Guanylate Cyclase (SGC) Stimulator
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pulmonary Arterial Hypertension Treatment Demand Share Forecast, 2019-2026
11. Europe Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
11.7.1. Vasodilators
11.7.2. Phosphodiesterase 5 (PDE 5) Inhibitors
11.7.3. Endothelin Receptor Antagonists (ERA)
11.7.4. Soluble Guanylate Cyclase (SGC) Stimulator
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pulmonary Arterial Hypertension Treatment Demand Share, 2019-2026
12. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
12.7.1. Vasodilators
12.7.2. Phosphodiesterase 5 (PDE 5) Inhibitors
12.7.3. Endothelin Receptor Antagonists (ERA)
12.7.4. Soluble Guanylate Cyclase (SGC) Stimulator
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pulmonary Arterial Hypertension Treatment Demand Share, 2019-2026
13. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size and Volume Forecast by Type
13.7.1. Vasodilators
13.7.2. Phosphodiesterase 5 (PDE 5) Inhibitors
13.7.3. Endothelin Receptor Antagonists (ERA)
13.7.4. Soluble Guanylate Cyclase (SGC) Stimulator
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pulmonary Arterial Hypertension Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pulmonary Arterial Hypertension Treatment Market: Market Share Analysis
14.2. Pulmonary Arterial Hypertension Treatment Distributors and Customers
14.3. Pulmonary Arterial Hypertension Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer Inc.Actelion Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. United Therapeutic Corporation
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. SteadyMed Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Gilead Sciences, Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Teva Pharmaceuticals Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bayer AG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
